Momelotinib is a highly potent inhibitor of FLT3-mutant AML

Despite the introduction of more selective FLT3 inhibitors to treat FLT3-mutated acute myeloid leukemia (AML), remissions are short lived, and patients show progressive disease after an initial response. Acquisition of resistance-conferring genetic mutations and growth factor signaling are 2 princip...

Descripción completa

Detalles Bibliográficos
Autores principales: Azhar, Mohammad, Kincaid, Zachary, Kesarwani, Meenu, Ahmed, Arhama, Wunderlich, Mark, Latif, Tahir, Starczynowski, Daniel, Azam, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Myeloid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864657/
https://www.ncbi.nlm.nih.gov/pubmed/34768286
http://dx.doi.org/10.1182/bloodadvances.2021004611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864657/
https://www.ncbi.nlm.nih.gov/pubmed/34768286
http://dx.doi.org/10.1182/bloodadvances.2021004611

Ejemplares similares